ArticleOncotarget2016
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.Cancer metastasis reviews · 2026Pooled it
- Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma.Frontiers in pharmacology · 2023Pooled it
- Web-Based Prediction Models for Overall Survival and Cancer-Specific Survival of Patients With Primary Urachal Carcinoma: A Study Based on SEER Database.Frontiers in public health · 2022Trial
- The Prognostic Significance of KRAS, NRAS, and BRAF Mutations in Colorectal Cancer: A Systematic Review and Meta-Analysis.Clinical Medicine Insights. Oncology · 2026Article
- Article
- Long-Term Survival Obtained by Repeated Cytoreductive Surgery and S-1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report.Cancer reports (Hoboken, N.J.) · 2025Article
- Surgical treatment of urachal adenocarcinoma with lung metastasis: A case report and literature review.Thoracic cancer · 2024Review
- Urachal adenocarcinoma with cervical invasion misdiagnosed as primary cervical adenocarcinoma: a case report and literature review.Frontiers in oncology · 2024Article
- Article
- Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.Cancer medicine · 2023Article
- Preoperative accuracy of diagnostic evaluation of urachal carcinoma.Cancer medicine · 2023Article
- Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group.Frontiers in oncology · 2023Article
- Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.JCO precision oncology · 2022Article
- Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice.European urology open science · 2022Review
- Clinical, Pathological, and Prognostic Analysis of Urachal Carcinoma.Urologia internationalis · 2022Article
- Construction and Validation of Novel Prediction Tools Based on Large Population-Based Database to Predict the Prognosis of Urachal Cancer After Surgery.Frontiers in oncology · 2021Article
- Prevalence of APC and PTEN Alterations in Urachal Cancer.Pathology oncology research : POR · 2020Article
- Urachal Carcinoma: Are Lymphadenectomy and Umbilectomy Necessary?Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Comparative genomic profiling of glandular bladder tumours.Virchows Archiv : an international journal of pathology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTargeted therapy represents an attractive alternative for rare tumors such as urachal carcinoma (UrC). The aim of this study was to assess the mutations of the most commonly affected 5 genes in the targetable EGFR-pathway in UrC and comapre their frequencies to those of found in urothelial and colorectal cancer. MATERIALS AND
methodsMutational hot-spots of selected genes were tested in 22 UrC samples by pyrosequencing. Mutational patterns were compared to those published for colorectal and urothelial cancers. Furthermore, we sought correlations between mutations and clinicopathological and follow-up data.
resultsWe found 11 mutations in 10 of 22 (45%) patients. The most frequently mutated gene was KRAS (27%) followed by BRAF (18%) and NRAS (5%), while no mutations were detected in the EGFR and PIK3CA genes. No correlation was found between the mutation status and clinicopathological parameters (Sheldon/Mayo stage, tumor grade, metastases). Furthermore, none of the mutations correlated with progression-free or overall survival.
conclusionsThe mutation pattern of UrC is more similar to colorectal than to urothelial cancer. However, the mutation characteristics of UrC seems to be unique suggesting that clinical decision-making for UrC cannot be simply adopted from urothelial or colorectal carcinoma. The high occurence of EGFR-pathway mutations warrants the testing for KRAS and BRAF mutations when considering anti-EGFR therapy in UrC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.